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SUPPLEMENTARY NOTES
ABSTRACT
OXCT1 is a key enzyme in ketone body metabolism and cellular energy homeostasis. Analysis of patient data indicated that higher OXCT1 levels are associated with docetaxel chemotherapy resistance. In order to investigate the role of OXCT1 in prostate cancer chemotherapy resistance and the underlying mechanisms, we established OXCT1 stable knock down prostate cancer cell lines. The results revealed that lowering OXCT1 level using shRNA knock down increased docetaxel chemosensitivity in prostate cancer cells. Lowering OXCT1 enhanced docetaxel induced JNK signaling pathway activation and downstream apoptotic signaling. OXCT1 knock down increased ADP/ATP, NAD + /NADH and oxygen consumption in docetaxel treated cells compared to control knock down cells, therefore induced metabolic inefficiency. These results confirmed our hypothesis that OXCT1 plays important role in prostate cancer chemotherapy sensitivity and revealed the mechanisms. 
Introduction
Ketone bodies are important alternative energy source other than glucose and fatty acids.
The role of ketone body utilization pathway in regulating prostate cancer resistance to docetaxel-based chemotherapy has never been tested. OXCT1 encodes the rate limiting enzyme converting ketone bodies to acetyl-CoA. The goal of this project is to investigate the role of OXCT1 in prostate cancer chemotherapy sensitivity and the underlying molecular mechanisms.
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Overall Project Summary
Current Objectives
To determine the role of OXCT1-mediated ketone body utilization in regulating prostate cancer cell response to docetaxel, cellular metabolism, and redox balance and investigate the molecular mechanisms.
Results
OXCT1 level is associated with chemoresistance in prostate cancer patients
Analysis of prostate cancer needle biopsy samples revealed that the OXCT1 gene was overexpressed in nearly 50% of patients (1) . Kaplan-Meier survival analysis indicated that higher OXCT1 level was associated with lower relapse free survival rate (Fig. 1) . Further analysis showed that in prostate cancer cells OXCT1 level was higher than benign cells ( OXCT1 protein in prostate cancer cell lines.
OXCT1 knock down increased docetaxel chemosensitivity in prostate cancer cells
To further investigate the role of OXCT1 in docetaxel chemosensitivity, we established OXCT1 stable knockdown cell lines in prostate cancer cells lines C42B and DU145 (Fig. 3 ). C42B DU145 
OXCT1 knock down induced metabolic inefficiency upon docetaxel treatment
Since OXCT1 is a metabolic enzyme involved in energy homeostasis, next, to investigate the mechanism of increased docetaxel sensitivity in OXCT1 knock down cells, we measured ATP and ADP levels and determined ADP/ATP ratio in cells. The results showed that docetaxel treatment did not alter ADT/ATP ratio in control knock down cells, while in OXCT1 knock down cells, docetaxel treatment significantly increased ADP/ATP ratio (Fig.   6 ). NADH is the metabolic substrate for mitochondrial oxidative phosphorylation and ATP 
The role of ketone body supplementation in docetaxel chemosensitivity
To further test the above hypothesis, we analyzed the effect of ketone body on cellular metabolism. The results showed siRNA knock down of OXCT1 induced similar growth inhibition in PC3 prostate cancer cells (Fig. 9A) . Treatment of PC3 cells with acetoacetate increased cellular ATP levels (Fig. 9B ) and decreased reactive oxygen species (ROS) levels (Fig. 9C) , indicating that supplementation of ketone body improved cellular metabolism. We next investigated whether supplementation of ketone body could abolish the enhanced docetaxel sensitivity in OXCT1 knock down cells. We find that the ketone body Lithium
Acetoacetate did not affect cell viability in low concentrations, but decreased cell viability in high concentrations, however, this may be due to the toxic effects of the compound's acidity (Fig. 10 upper) . Based on the above results, next, we chose 3 Lithium Acetoacetate concentrations (low, medium and high) and combined them with docetaxel to evaluate the effect of ketone body on chemosensitivity in shOXCT1 cells. The results showed that docetaxel decreased cell viability in both shC and shOXCT1 cell lines, while Lithium Acetoacetate did not alter the effect of docetaxel (Fig. 10 lower) , suggesting that supplementation of ketone body alone may not alter docetaxel sensitivity in OXCT1 knock down cells. Analysis of our previous data from patient needle biopsy samples indicated that higher OXCT1 levels are associated with docetaxel chemotherapy resistance. In addition, we found that OXCT1 levels were higher in prostate cancer cells. 
Key Research Accomplishments
a. OXCT1 was associated with prostate cancer chemotherapy resistance in patients, and higher OXCT1 levels were detected in prostate cancer cell lines.
b. Lowering OXCT1 increased prostate cancer cell chemosensitivity to docetaxel.
c. Lowering OXCT1 increased chemosensitivity through increasing JNK signaling pathway and inducing metabolic inefficiency.
Conclusion
The current work confirms the hypothesis that OXCT1 regulates prostate cancer cell chemotherapy resistance, and revealed the underlying mechanisms, suggesting a new potential therapeutic strategy to improve prostate cancer chemotherapy.
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Reportable Outcomes
a. OXCT1 levels are upregulated in a subset of prostate cancer patients and prostate cancer cell lines.
b. OXCT1 upregulation was associated with prostate cancer chemotherapy resistance.
Lowering OXCT1 increased docetaxel chemosensitivity in prostate cancer cells.
c. Knock down of OXCT1 increased JNK signaling pathway and induced metabolic inefficiency upon docetaxel treatment.
Other Achievements
OXCT1 stable cell lines were developed.
